Research Progress of Alzheimer’s Disease Therapeutic Drugs: Based on Renin-Angiotensin System Axis
| Autor: | Da-Bao Chen, Yan Wang, Qiaoru Guo, Xinquan Li, Guangyun Wang, Wei-Ting Xuan, Hang Song, Hua-Wu Gao, Biao Cai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Angiotensin-Converting Enzyme Inhibitors Disease Renin-Angiotensin System Pathogenesis Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Renin–angiotensin system Humans Medicine Neuroinflammation Inflammation Amyloid beta-Peptides Mechanism (biology) business.industry General Neuroscience Cognition General Medicine Calcium Channel Blockers Clinical trial Oxidative Stress Psychiatry and Mental health Clinical Psychology 030104 developmental biology Geriatrics and Gerontology business Neuroscience 030217 neurology & neurosurgery |
| Zdroj: | Journal of Alzheimer's Disease. 78:1315-1338 |
| ISSN: | 1875-8908 1387-2877 |
| DOI: | 10.3233/jad-200770 |
| Popis: | It is widely recognized that Alzheimer’s disease (AD) has a complicate link to renin-angiotensin system (RAS). It is known that cerebrovascular disease has some connections with AD, but most of the studies are still conducted in parallel or independently. Although previous research came up with large number of hypotheses about the pathogenesis of AD, it does not include the mechanism of RAS-related regulation of AD. It has been found that many components of RAS have been changed in AD. For example, the multifunctional and high-efficiency vasoconstrictor Ang II and Ang III with similar effects are changed under the action of other RAS signal peptides; these signal peptides are believed to help improve nerve injury and cognitive function. These changes may lead to neuropathological changes of AD, and progressive defects of cognitive function, which are association with some hypotheses of AD. The role of RAS in AD gradually attracts our attention, and RAS deserved to be considered carefully in the pathogenesis of AD. This review discusses the mechanisms of RAS participating in the three current hypotheses of AD: neuroinflammation, oxidative stress and amyloid-β protein (Aβ) hypothesis, as well as the drugs that regulate RAS systems already in clinical or in clinical trials. It further demonstrates the importance of RAS in the pathogenesis of AD, not only because of its multiple aspects of participation, which may be accidental, but also because of the availability of RAS drugs, which can be reused as therapies of AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|